Hi Gary, TGIF! I like your insights. I think the Multiple Myeloma indication in the Orphan Drug review process with the FDA expedited FDA review process for Orphan Drugs would enhance our goals in a shorter time frame of ~ 1 year tremendously?

Cheers!

TappyS